EcoDrugPlus

Integrin Subunit Beta 8

Ensembl ID : ENSPFOG00000001324
Gene Symbol: ITGB8
1 Cross references
202 Possible Orthologues:

Integrin, Alpha 2b

Ensembl ID : ENSPFOG00000017967
Gene Symbol: ITGA2B
1 Cross references
190 Possible Orthologues:

Integrin, Alpha V

Ensembl ID : ENSPFOG00000000857
Gene Symbol: ITGAV
1 Cross references
237 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSPFOG00000007106
Gene Symbol: IRAK4
1 Cross references
200 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4-Like

Ensembl ID : ENSPFOG00000007094
Gene Symbol: LOC103134442
3 Cross references
199 Possible Orthologues:

Inward Rectifier Potassium Channel 2-Like

Ensembl ID : ENSPFOG00000020440
Gene Symbol: LOC103150732
4 Cross references
204 Possible Orthologues:

Inward Rectifier Potassium Channel 2-Like

Ensembl ID : ENSPFOG00000020437
Gene Symbol: LOC103150732
4 Cross references
203 Possible Orthologues:

Inward Rectifier Potassium Channel 2-Like

Ensembl ID : ENSPFOG00000020438
Gene Symbol: LOC103150732
4 Cross references
203 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSPFOG00000002594
Gene Symbol: IDH1
3 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp], Mitochondrial

Ensembl ID : ENSPFOG00000005967
Gene Symbol: LOC103147849
3 Cross references
207 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp], Mitochondrial-Like

Ensembl ID : ENSPFOG00000017364
Gene Symbol: LOC103135997
4 Cross references
186 Possible Orthologues:

Jeltraxin-Like

Ensembl ID : ENSPFOG00000018004
Gene Symbol: LOC103140901
2 Cross references
391 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).